These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
109 related articles for article (PubMed ID: 32473599)
1. A real-time cell-binding assay reveals dynamic features of STxB-Gb3 cointernalization and STxB-mediated cargo delivery into cancer cells. Encarnação JC; Napolitano V; Opassi G; Danielson UH; Dubin G; Popowicz GM; Munier-Lehmann H; Buijs J; Andersson K; Björkelund H FEBS Lett; 2020 Aug; 594(15):2406-2420. PubMed ID: 32473599 [TBL] [Abstract][Full Text] [Related]
2. Gastric Adenocarcinomas Express the Glycosphingolipid Gb3/CD77: Targeting of Gastric Cancer Cells with Shiga Toxin B-Subunit. Geyer PE; Maak M; Nitsche U; Perl M; Novotny A; Slotta-Huspenina J; Dransart E; Holtorf A; Johannes L; Janssen KP Mol Cancer Ther; 2016 May; 15(5):1008-17. PubMed ID: 26826119 [TBL] [Abstract][Full Text] [Related]
3. Potent in vitro antitumor activity of B-subunit of Shiga toxin conjugated to the diphtheria toxin against breast cancer. Mohseni Z; Sedighian H; Halabian R; Amani J; Behzadi E; Imani Fooladi AA Eur J Pharmacol; 2021 May; 899():174057. PubMed ID: 33753109 [TBL] [Abstract][Full Text] [Related]
4. Intracellular drug delivery: Potential usefulness of engineered Shiga toxin subunit B for targeted cancer therapy. Luginbuehl V; Meier N; Kovar K; Rohrer J Biotechnol Adv; 2018; 36(3):613-623. PubMed ID: 29432805 [TBL] [Abstract][Full Text] [Related]
5. Membrane invagination induced by Shiga toxin B-subunit: from molecular structure to tube formation. Pezeshkian W; Hansen AG; Johannes L; Khandelia H; Shillcock JC; Kumar PB; Ipsen JH Soft Matter; 2016 Jun; 12(23):5164-71. PubMed ID: 27070906 [TBL] [Abstract][Full Text] [Related]
6. Trafficking of Shiga toxin/Shiga-like toxin-1 in human glomerular microvascular endothelial cells and human mesangial cells. Warnier M; Römer W; Geelen J; Lesieur J; Amessou M; van den Heuvel L; Monnens L; Johannes L Kidney Int; 2006 Dec; 70(12):2085-91. PubMed ID: 17063173 [TBL] [Abstract][Full Text] [Related]
7. Tumor delivery of ultrasound contrast agents using Shiga toxin B subunit. Couture O; Dransart E; Dehay S; Nemati F; Decaudin D; Johannes L; Tanter M Mol Imaging; 2011 Apr; 10(2):135-43. PubMed ID: 21439258 [TBL] [Abstract][Full Text] [Related]
8. Differential recognition of lipid domains by two Gb3-binding lectins. Schubert T; Sych T; Madl J; Xu M; Omidvar R; Patalag LJ; Ries A; Kettelhoit K; Brandel A; Mely Y; Steinem C; Werz DB; Thuenauer R; Römer W Sci Rep; 2020 Jun; 10(1):9752. PubMed ID: 32546842 [TBL] [Abstract][Full Text] [Related]
9. Repurposing the Pentameric B-Subunit of Shiga Toxin for Gb3-Targeted Immunotherapy of Colorectal Cancer by Rhamnose Conjugation. Liu Z; Li X; Lu Z; Qin X; Hong H; Zhou Z; Pieters RJ; Shi J; Wu Z J Pharm Sci; 2022 Oct; 111(10):2719-2729. PubMed ID: 35905973 [TBL] [Abstract][Full Text] [Related]
10. Human breast cancer and lymph node metastases express Gb3 and can be targeted by STxB-vectorized chemotherapeutic compounds. Stimmer L; Dehay S; Nemati F; Massonnet G; Richon S; Decaudin D; Klijanienko J; Johannes L BMC Cancer; 2014 Dec; 14():916. PubMed ID: 25476116 [TBL] [Abstract][Full Text] [Related]
11. Gb3-binding lectins as potential carriers for transcellular drug delivery. Müller SK; Wilhelm I; Schubert T; Zittlau K; Imberty A; Madl J; Eierhoff T; Thuenauer R; Römer W Expert Opin Drug Deliv; 2017 Feb; 14(2):141-153. PubMed ID: 27935765 [TBL] [Abstract][Full Text] [Related]
12. Intracellular trafficking of Shiga-toxin-B-subunit-functionalized spherulites. Bouter A; Delord B; Dransart E; Poirier C; Johannes L; van Effenterre D Biol Cell; 2008 Dec; 100(12):717-25. PubMed ID: 18564063 [TBL] [Abstract][Full Text] [Related]
13. Shiga toxin and its use in targeted cancer therapy and imaging. Engedal N; Skotland T; Torgersen ML; Sandvig K Microb Biotechnol; 2011 Jan; 4(1):32-46. PubMed ID: 21255370 [TBL] [Abstract][Full Text] [Related]
14. Tumor-specific targeting of pancreatic cancer with Shiga toxin B-subunit. Maak M; Nitsche U; Keller L; Wolf P; Sarr M; Thiebaud M; Rosenberg R; Langer R; Kleeff J; Friess H; Johannes L; Janssen KP Mol Cancer Ther; 2011 Oct; 10(10):1918-28. PubMed ID: 21788400 [TBL] [Abstract][Full Text] [Related]
15. In vivo tumor targeting by the B-subunit of shiga toxin. Viel T; Dransart E; Nemati F; Henry E; Thézé B; Decaudin D; Lewandowski D; Boisgard R; Johannes L; Tavitian B Mol Imaging; 2008; 7(6):239-47. PubMed ID: 19123994 [TBL] [Abstract][Full Text] [Related]
16. Human colorectal tumors and metastases express Gb3 and can be targeted by an intestinal pathogen-based delivery tool. Falguières T; Maak M; von Weyhern C; Sarr M; Sastre X; Poupon MF; Robine S; Johannes L; Janssen KP Mol Cancer Ther; 2008 Aug; 7(8):2498-508. PubMed ID: 18687997 [TBL] [Abstract][Full Text] [Related]
17. Tumor Targeting with Bacterial Shiga Toxin B Subunit in Genetic Porcine Models for Colorectal Cancer and Osteosarcoma. Ehrenfeld M; Schrade A; Flisikowska T; Perl M; Hirsch ND; Sichler A; Geyer L; Flisikowski K; Wilhelm D; Schober SJ; Johannes L; Schnieke A; Janssen KP Mol Cancer Ther; 2022 Apr; 21(4):686-699. PubMed ID: 35086950 [TBL] [Abstract][Full Text] [Related]
19. The Shiga toxin B-subunit targets antigen in vivo to dendritic cells and elicits anti-tumor immunity. Vingert B; Adotevi O; Patin D; Jung S; Shrikant P; Freyburger L; Eppolito C; Sapoznikov A; Amessou M; Quintin-Colonna F; Fridman WH; Johannes L; Tartour E Eur J Immunol; 2006 May; 36(5):1124-35. PubMed ID: 16568496 [TBL] [Abstract][Full Text] [Related]
20. Key role of receptor density in colloid/cell specific interaction: a quantitative biomimetic study on giant vesicles. Lamblet M; Delord B; Johannes L; van Effenterre D; Bassereau P Eur Phys J E Soft Matter; 2008; 26(1-2):205-16. PubMed ID: 18480963 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]